Long term mortality in hormone-treated transsexuals

Dr Henk Asscheman

This study assessed mortality in a cohort of 1330 transsexuals: 965 male-to-female (MtF), mean age at start 31.4 years, 13,935 patient-years and 365 female-to-male (FtM), mean age at start 26.1 years, 5,550 patient-years. All patients who had started hormones before July 1, 1997 were included and followed till death, last visit or July 1, 2007. Causes of death (ICD-10) were ascertained by medical reports or general practioners.

Conflict of Interest: None disclosed
Financial Support/Funding: None disclosed
Recorded at 19th WAS World Congress for Sexual Health - Sexual Health & Rights: A Global Challenge Göteborg (Sweden) - June 21 – 25, 2009

Henk Asscheman
Henk Asscheman
  more about this speaker
  other talks by the speaker
XShare
Click on a link above to share this page with your networking site.

Media     

TITLE SPEAKER DURATION
VideoLong term mortality in hormone-treated transsexualsHenk Asscheman10'19"
icon pdf.gifLong term mortality in hormone-treated transsexualsHenk Asscheman 
icon mp3.gifLong term mortality in hormone-treated transsexualsHenk Asscheman 


Top of page

Dr Henk Asscheman

Consultant internal medicine, HAJAP, Valeriusstraat 4HS, 1071MH Amsterdam, The Netherlands.

Co-authors: Erik J Giltay1, Jos AJ Megens2, Louis JG Gooren2, 1Dept of Psychiatry, Leiden University Medical Center, 2Dept. of Endocrinology, Vrije Universiteit Medical Center, Amsterdam
Top of page
Subscribers
Login Here
Email
Password
Subscribe
Now
BENEFIT from
UNLIMITED ACCESS to our
GROWING VIDEO LIBRARY
 
 
 
$19.95 - Unlimited Access
 
 
 
$99.75 - Save 1 Month
 
 
 
$149.95 - Save 3 Months
WAS - World Association fro Sexual HealthSociety of Australian SexologiestsAustralian Centre for Sexual HealthashnAOFSCSEPI - Council of Sex Education and Parenthood (International)SASSM